Evaluation of ICP-B794 in Patients With Advanced Solid Tumors

Phase 1 Not yet recruiting 410 enrolled Beijing InnoCare Pharma Tech Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

An Open-Label, Multi-center, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ICP-B794 in Patients with Advanced Solid Tumors

Timeline

Start: 2025-08
Primary completion: 2029-06
Completion: 2030-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ICP-B794	Unknown	—	Intravenous

Evaluation of ICP-B794 in Patients With Advanced Solid Tumors

Summary

Timeline

Drugs

Indications